2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A hybrid semiconducting organosilica-based O 2 nanoeconomizer for on-demand synergistic photothermally boosted radiotherapy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The outcome of radiotherapy is significantly restricted by tumor hypoxia. To overcome this obstacle, one prevalent solution is to increase intratumoral oxygen supply. However, its effectiveness is often limited by the high metabolic demand for O 2 by cancer cells. Herein, we develop a hybrid semiconducting organosilica-based O 2 nanoeconomizer pHPFON-NO/O 2 to combat tumor hypoxia. Our solution is twofold: first, the pHPFON-NO/O 2 interacts with the acidic tumor microenvironment to release NO for endogenous O 2 conservation; second, it releases O 2 in response to mild photothermal effect to enable exogenous O 2 infusion. Additionally, the photothermal effect can be increased to eradicate tumor residues with radioresistant properties due to other factors. This “reducing expenditure of O 2 and broadening sources” strategy significantly alleviates tumor hypoxia in multiple ways, greatly enhances the efficacy of radiotherapy both in vitro and in vivo, and demonstrates the synergy between on-demand temperature-controlled photothermal and oxygen-elevated radiotherapy for complete tumor response.

          Abstract

          Tumor hypoxia is a major limitation in radiotherapy, and strategies to address this often fail due to high oxygen consumption. Here, the authors report a nanomaterial assembly for the simultaneous reduction in mitochondrial respiration and to supply oxygen to potentiate radiotherapy.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Otto Warburg's contributions to current concepts of cancer metabolism.

          Otto Warburg pioneered quantitative investigations of cancer cell metabolism, as well as photosynthesis and respiration. Warburg and co-workers showed in the 1920s that, under aerobic conditions, tumour tissues metabolize approximately tenfold more glucose to lactate in a given time than normal tissues, a phenomenon known as the Warburg effect. However, this increase in aerobic glycolysis in cancer cells is often erroneously thought to occur instead of mitochondrial respiration and has been misinterpreted as evidence for damage to respiration instead of damage to the regulation of glycolysis. In fact, many cancers exhibit the Warburg effect while retaining mitochondrial respiration. We re-examine Warburg's observations in relation to the current concepts of cancer metabolism as being intimately linked to alterations of mitochondrial DNA, oncogenes and tumour suppressors, and thus readily exploitable for cancer therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

            Recent epidemiological and laboratory-based studies suggest that the anti-diabetic drug metformin prevents cancer progression. How metformin diminishes tumor growth is not fully understood. In this study, we report that in human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration. Metformin inhibited cellular proliferation in the presence of glucose, but induced cell death upon glucose deprivation, indicating that cancer cells rely exclusively on glycolysis for survival in the presence of metformin. Metformin also reduced hypoxic activation of hypoxia-inducible factor 1 (HIF-1). All of these effects of metformin were reversed when the metformin-resistant Saccharomyces cerevisiae NADH dehydrogenase NDI1 was overexpressed. In vivo, the administration of metformin to mice inhibited the growth of control human cancer cells but not those expressing NDI1. Thus, we have demonstrated that metformin's inhibitory effects on cancer progression are cancer cell autonomous and depend on its ability to inhibit mitochondrial complex I. DOI: http://dx.doi.org/10.7554/eLife.02242.001
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.

              Radiotherapy plays a central part in curing cancer. For decades, most research on improving treatment outcomes has focused on modulating radiation-induced biological effects on cancer cells. Recently, we have better understood that components within the tumour microenvironment have pivotal roles in determining treatment outcomes. In this Review, we describe vascular, stromal and immunological changes that are induced in the tumour microenvironment by irradiation and discuss how these changes may promote radioresistance and tumour recurrence. We also highlight how this knowledge is guiding the development of new treatment paradigms in which biologically targeted agents will be combined with radiotherapy.
                Bookmark

                Author and article information

                Contributors
                beijinyz@126.com
                wenpei.fan@cpu.edu.cn
                chen.shawn@nus.edu.sg
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                22 January 2021
                22 January 2021
                2021
                : 12
                Affiliations
                [1 ]GRID grid.94365.3d, ISNI 0000 0001 2297 5165, Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, , National Institutes of Health, ; Bethesda, MD 20892 USA
                [2 ]GRID grid.64924.3d, ISNI 0000 0004 1760 5735, State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, , Jilin University, ; 130012 Changchun, P.R. China
                [3 ]GRID grid.8547.e, ISNI 0000 0001 0125 2443, Institute of Radiation Medicine, , Fudan University, ; 200032 Shanghai, P.R. China
                [4 ]GRID grid.411604.6, ISNI 0000 0001 0130 6528, MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, , Fuzhou University, ; 350116 Fuzhou, P.R. China
                [5 ]GRID grid.9227.e, ISNI 0000000119573309, State Key Laboratory of High-Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, , Chinese Academy of Sciences, ; 200050 Shanghai, P.R. China
                [6 ]GRID grid.254147.1, ISNI 0000 0000 9776 7793, State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, , China Pharmaceutical University, ; 210009 Nanjing, P.R. China
                [7 ]GRID grid.4280.e, ISNI 0000 0001 2180 6431, Yong Loo Lin School of Medicine and Faculty of Engineering, , National University of Singapore, ; 117597 Singapore, Singapore
                Article
                20860
                10.1038/s41467-020-20860-3
                7822893
                33483518
                c06017b2-aa72-4800-99e7-2020273353ba
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                Funding
                Funded by: FundRef https://doi.org/10.13039/501100011002, National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund);
                Award ID: 21874024
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100000070, U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB);
                Award ID: ZIA EB000073
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                radiotherapy,targeted therapies,nanotechnology in cancer
                Uncategorized
                radiotherapy, targeted therapies, nanotechnology in cancer

                Comments

                Comment on this article